Impact of the PEAR 1 polymorphism on clinical outcomes in Chinese patients receiving dual antiplatelet therapy after percutaneous coronary intervention

References

• 1. Neumann F, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 14(14), 1435–1534 (2019).
  MedlineGoogle Scholar
• 2. Amin A, Sheau Chin L, Teh C et al. Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. Eur J Pharm Sci. 117, 351–361 (2018).
  Medline CASGoogle Scholar
• 3. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 360(4), 363–375 (2009).
  Medline CASGoogle Scholar
• 4. Hulot J, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 108(7), 2244–2247 (2006).
  Medline CASGoogle Scholar
• 5. Becker D, Segal J, Vaidya D et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 295(12), 1420–1427 (2006).
  Medline CASGoogle Scholar
• 6. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809–1817 (2001).
  Medline CASGoogle Scholar
• 7. Xu K, Ye S, Zhang S et al. Impact of platelet endothelial aggregation receptor-1 genotypes on platelet reactivity and early cardiovascular outcomes in patients undergoing percutaneous coronary intervention and treated with aspirin and clopidogrel. Circ Cardiovasc Interv. 12(5), e007019 (2019).
  Medline CASGoogle Scholar
• 8. Li X, Ma N, Li X et al. Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting. PLOS ONE 11(2), e0148891 (2016).
  MedlineGoogle Scholar
• 9. Duconge J, Santiago E, Hernandez-Suarez D et al. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: a candidate gene approach. Clin. Transl. Sci. 14(6), 2254–2266 (2021).
  Medline CASGoogle Scholar
• 10. Nanda N, Bao M, Lin H et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J. Biol. Chem. 280(26), 24680–24689 (2005).
  Medline CASGoogle Scholar
• 11. Keramati A, Chen M, Rodriguez B et al. Genome sequencing unveils a regulatory landscape of platelet reactivity. Nat. Commun. 12(1), 3626 (2021).
  Medline CASGoogle Scholar
• 12. Faraday N, Yanek L, Yang X et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12), 3367–3375 (2011).
  Medline CASGoogle Scholar
• 13. Li Z, Jiang H, Ding Y et al. Platelet endothelial aggregation receptor 1 polymorphism is associated with functional outcome in small-artery occlusion stroke patients treated with aspirin. Front Cardiovasc. Med. 8, 664012 (2021).
  MedlineGoogle Scholar
• 14. Collet J, Cuisset T, Rangé G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367(22), 2100–2109 (2012).
  Medline CASGoogle Scholar
• 15. Deng Q, Hou J, Deng X, Zhong ZJP. Association of serum laboratory parameters with periprocedural myocardial infarction after a primary percutaneous coronary intervention. Perfusion. 2676591211057502 (2022).
  Google Scholar
• 16. Guo Y, Zhao J, Zhang Y et al. Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients. BMC Neurol. 21(1), 409 (2021).
  Medline CASGoogle Scholar